XML 66 R13.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 12 Months Ended
Dec. 31, 2025
Segment Information [Abstract]  
Segment Information

6. Segment Information

 

The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company’s costs associated with the preclinical and clinical development of the Company’s product candidates. The Company currently is in the clinical stage and manages its business activities on an aggregate basis.

 

The accounting policies of the lysosomal storage disorders segment are consistent with those described in Note 2, Summary of Significant Accounting Policies, and the measure of segment assets is reported on the balance sheets as total assets. The Company’s CODM is the chief executive officer. The CODM assesses performance of the lysosomal storage disorders segment using operating expenses as reported in the statements of operations and comprehensive loss. Operating expenses is assessed by the CODM to make decisions on how to allocate resources, such as determining additional costs for preclinical and clinical development of the Company’s product candidates.

 

The following table summarized significant segment expenses for the years ended December 31, 2025 and 2024:

 

   Lysosomal Storage
Disorders Segment		 
   Year Ended December 31, 
   2025   2024 
   (In thousands) 
Research and development expenses (excluding stock compensation) $(1,922) $(1,077)
General and administrative expenses (excluding stock compensation)  (1,174)  (875)
Stock-based compensation  (4,725)  (2,400)
Recapitalization of common stock  —   (26,004)
Other expense – direct listing offering costs  (1,164)  — 
Net loss $(8,985) $(30,356)